Bromocriptine in depression.

A double-blind trial was carried out in 9 patients with endogenous depression to compare the effectiveness of bromocriptine (15 mg per day, 4 patients) with that of imipramine (75 mg per day, 5 patients) over a period of 10 weeks. The results of assessments using the Hamilton Rating Scale for Depression showed that both drugs produced comparable reduction in mean scores and there was no significant difference between the two treatment groups. Fewer patients han anticholinergic type side-effects on bromocriptine although some had transient nausea.

RCT Entities:   Population Interventions Outcomes